S. Collazo-Caballero

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial

E. García‐Iglesias, I. García-García, I. Bello-Rivero, 2012, BMC Pharmacology and Toxicology.

Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON

C. Valenzuela-Silva, M. rodríguez-garCía, E. García‐Iglesias, 2022, medRxiv.

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial

E. García‐Iglesias, I. García-García, I. Bello-Rivero, 2012, BMC Pharmacology and Toxicology.